Kyn Therapeutics and Merck begin Phase Ib/I trials of ARY-007
Kyn Therapeutics in collaboration with Merck has commenced two clinical trials of EP4 receptor antagonist ARY-007.
Kyn Therapeutics in collaboration with Merck has commenced two clinical trials of EP4 receptor antagonist ARY-007.